However , in 2010 , mapatumumab failed in a midstage study .
In 2008 HGS reported initial results of a randomised phase 2 trial of mapatumumab in combination with bortezomib in advanced multiple myeloma .
In 2010 , mapatumumab failed in a midstage study .
In 2008 HGS reported initial results of a randomised phase 2 trial of mapatumumab in combination with bortezomib in advanced multiple myeloma .